Oxford Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Oxford Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-443,962	Closed	-$1.84M	–	820
2019 Q4	$1.84M	Buy	+443,962	New	+$1.71M	0.05%	468
2017 Q3	–	Sell	-104,837	Closed	-$1.73M	–	1629
2017 Q2	$1.73M	Buy	+104,837	New	+$1.62M	0.03%	671
2016 Q4	–	Sell	-277,954	Closed	-$5.02M	–	832
2016 Q3	$5.02M	Sell	277,954 -109,429	-28%	-$1.76M	0.16%	150
2016 Q2	$5.56M	Buy	387,383 +60,623	+19%	+$822K	0.18%	128
2016 Q1	$3.9M	Buy	326,760 +222,783	+214%	+$2.34M	0.11%	226
2015 Q4	$1.39M	Sell	103,977 -43,812	-30%	-$539K	0.03%	462
2015 Q3	$1.59M	Buy	147,789 +43,164	+41%	+$471K	0.05%	330
2015 Q2	$842K	Buy	+104,625	New	+$768K	0.02%	466
2015 Q1	–	Sell	-11,101	Closed	-$67K	–	707
2014 Q4	$67K	Buy	+11,101	New	+$89.5K	﹤0.01%	665

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Oxford Asset Management's LXRX Position: Q1 2020 in Review

Oxford Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2020, closing a stake of 443,962 shares — an estimated $1.84M sold.

Oxford Asset Management first reported a position in LXRX in Q4 2014 and held it in 9 quarters. The position peaked at $5.56M in Q2 2016. 113 funds tracked by Wall St. Rank hold LXRX as of Q1 2020.

Oxford Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 443,962 Lexicon Pharmaceuticals shares in Q1 2020, an estimated $1.84M.
Oxford Asset Management first reported a position in Lexicon Pharmaceuticals in Q4 2014 and held it in 9 quarters.
Oxford Asset Management's Lexicon Pharmaceuticals position peaked at $5.56M in Q2 2016.
113 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.